Immuneering Corp (IMRX) concluded trading on Thursday at a closing price of $1.97, with 8.03 million shares of worth about $15.82 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 16.57% during that period and on December 12, 2024 the price saw a loss of about -7.94%. Currently the company’s common shares owned by public are about 31.05M shares, out of which, 22.40M shares are available for trading.
Stock saw a price change of -7.94% in past 5 days and over the past one month there was a price change of 7.65%. Year-to-date (YTD), IMRX shares are showing a performance of -73.20% which decreased to -69.83% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.00 but also hit the highest price of $8.41 during that period. The average intraday trading volume for Immuneering Corp shares is 5.49 million. The stock is currently trading -4.81% below its 20-day simple moving average (SMA20), while that difference is down -5.28% for SMA50 and it goes to -0.41% lower than SMA200.
Immuneering Corp (NASDAQ: IMRX) currently have 31.05M outstanding shares and institutions hold larger chunk of about 14.04% of that.
The stock has a current market capitalization of $61.17M and its 3Y-monthly beta is at -0.33. It has posted earnings per share of -$1.97 in the same period. It has Quick Ratio of 7.99 while making debt-to-equity ratio of 0.07. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for IMRX, volatility over the week remained 8.17% while standing at 9.08% over the month.
Stock’s fiscal year EPS is expected to rise by 3.28% while it is estimated to increase by 13.93% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Needham on March 15, 2024 offering a Buy rating for the stock and assigned a target price range of between $20 and $15 to it. On March 15, 2024, Jefferies Downgrade their recommendations, while on December 01, 2023, Needham Initiated their ratings for the stock with a price target of $20. Stock get an Outperform rating from Oppenheimer on June 26, 2023.
